<?xml version="1.0" encoding="UTF-8"?>
<p id="para0006">In a separate study in Dar es Salaam, Tanzania, Scott and colleagues quantify the substantial economic cost of HCV disease among PWID, estimated to be nearly USD$30 million over 2018–2030 (
 <xref rid="bib0010" ref-type="bibr">Scott et al., 2019</xref>). Their dynamic model indicates important benefits of existing harm reduction programs in preventing HCV. They additionally show that testing and treatment programs are likely to be cost-effective, with HCV core antigen (HCVcAg) testing potentially having greater impact compared to antibody and confirmatory PCR as a result of its simplified diagnostic process and resulting better retention in care.
</p>
